custom image

Targeted Protein Degradation: From Small Molecules to Complex Organelles

June 7-8, 2021 | 10:00AM EDT | 2:00PM UTC | 4:00PM CEST*
*Program is in development and subject to change

Advanced Filters

We aspire to be the premier research-intensive biopharmaceutical company in the world

For more than 125 years, Merck (known as MSD outside of the U.S. and Canada) has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives.

We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.

Today, we continue to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases.


Targeted protein degradation is an innovative pharmacological paradigm that has revolutionized the way we think about drugs. Most conventional small molecules only block specific functions of disease-causing proteins and are limited to a very restricted target space. Molecular glue degraders instead cause the complete elimination of harmful proteins and constitute a new avenue towards targeting proteins that were previously considered “undruggable”. Molecular glue degraders have been historically difficult to identify. At Proxygen, we have developed rational discovery assays that, for the first time, enable the identification and development of novel glue degraders at scale, putting us at the forefront of charting this unexplored chemical space.